reMYND NV – Product Pipeline Review

Global Markets Direct’s, ‘reMYND NV – Product Pipeline Review – 2016’, provides an overview of the reMYND NV’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by reMYND NV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of reMYND NV

The report provides overview of reMYND NV including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses reMYND NV’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features reMYND NV’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate reMYND NV’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for reMYND NV

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding reMYND NV’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

reMYND NV Snapshot 5

reMYND NV Overview 5

Key Facts 5

reMYND NV - Research and Development Overview 6

Key Therapeutic Areas 6

reMYND NV - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

reMYND NV - Pipeline Products Glance 10

reMYND NV - Early Stage Pipeline Products 10

Preclinical Products/Combination Treatment Modalities 10

Discovery Products/Combination Treatment Modalities 11

reMYND NV - Drug Profiles 12

ReS-10T - Drug Profile 12

Product Description 12

Mechanism Of Action 12

R&D Progress 12

ReS-12S - Drug Profile 13

Product Description 13

Mechanism Of Action 13

R&D Progress 13

ReS-13I - Drug Profile 14

Product Description 14

Mechanism Of Action 14

R&D Progress 14

ReS-19T - Drug Profile 15

Product Description 15

Mechanism Of Action 15

R&D Progress 15

ReS-39I - Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

ReS-3T - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

ReS-8T - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

ReS-9S - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

Small Molecules for Amyotrophic Lateral Sclerosis - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

Small Molecules to Inhibit Huntingtin Protein for Huntington’s Disease - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

reMYND NV - Pipeline Analysis 22

reMYND NV - Pipeline Products by Target 22

reMYND NV - Pipeline Products by Molecule Type 23

reMYND NV - Pipeline Products by Mechanism of Action 24

reMYND NV - Locations And Subsidiaries 25

Head Office 25

Appendix 26

Methodology 26

Coverage 26

Secondary Research 26

Primary Research 26

Expert Panel Validation 26

Contact Us 26

Disclaimer 27

List of Tables

List of Tables

reMYND NV, Key Facts 5

reMYND NV – Pipeline by Indication, 2016 7

reMYND NV – Pipeline by Stage of Development, 2016 8

reMYND NV – Monotherapy Products in Pipeline, 2016 9

reMYND NV – Preclinical, 2016 10

reMYND NV – Discovery, 2016 11

reMYND NV – Pipeline by Target, 2016 22

reMYND NV – Pipeline by Molecule Type, 2016 23

reMYND NV – Pipeline Products by Mechanism of Action, 2016 24

List of Figures

List of Figures

reMYND NV – Pipeline by Indication, 2016 7

reMYND NV – Pipeline by Stage of Development, 2016 8

reMYND NV – Monotherapy Products in Pipeline, 2016 9

reMYND NV – Pipeline by Target, 2016 22

reMYND NV – Pipeline by Molecule Type, 2016 23

reMYND NV – Pipeline Products by Mechanism of Action, 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports